Customize your JAMA Network experience by selecting one or more topics from the list below.
Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial Reactivity in Healthy Individuals Undergoing Long-term Topical Treatment With β-Blockers. Arch Ophthalmol. 2005;123(1):35–38. doi:10.1001/archopht.123.1.35
To assess the impact of long-term treatment with topical timolol on bronchial reactivity in healthy individuals.
Twenty-one otherwise healthy individuals with high-pressure primary open-angle glaucoma were enrolled in a randomized controlled clinical trial. Eleven patients underwent 3 years of topical 0.5% timolol treatment followed by a 1-year washout period; 10 patients underwent primary argon laser trabeculoplasty. Functional variables and bronchial reactivity (forced expiratory volume in 1 second and metacholine challenge test results) were assessed in both groups at enrollment and after 3 and 4 years of follow-up.
After 3 years, a measurable response to metacholine challenge was recorded in 6 of 11 otherwise symptom-free individuals treated with 0.5% timolol twice daily. A detectable response to metacholine challenge was still present in half of these individuals (3 of 6) when further washed out for 1 year from the topical β-blocker. No significant variation in bronchial reactivity was measured in the laser-treated group during 4 years of follow-up.
Healthy individuals who undergo long-term topical application of a nonselective β-blocker (0.5% timolol) can develop a subclinical increase in bronchial reactivity. This phenomenon may not be completely reversible on withdrawal of the β-blocker.
Create a personal account or sign in to: